[go: up one dir, main page]

WO2003062370B1 - Proteines multimeres et methodes de production et d'utilisation de ces proteines - Google Patents

Proteines multimeres et methodes de production et d'utilisation de ces proteines

Info

Publication number
WO2003062370B1
WO2003062370B1 PCT/US2002/023003 US0223003W WO03062370B1 WO 2003062370 B1 WO2003062370 B1 WO 2003062370B1 US 0223003 W US0223003 W US 0223003W WO 03062370 B1 WO03062370 B1 WO 03062370B1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
multimeric protein
multimerization
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/023003
Other languages
English (en)
Other versions
WO2003062370A2 (fr
WO2003062370A3 (fr
Filing date
Publication date
Application filed filed Critical
Priority to JP2003562238A priority Critical patent/JP2005522192A/ja
Priority to EP02804525A priority patent/EP1578917A4/fr
Priority to CA002454358A priority patent/CA2454358A1/fr
Priority to AU2002365196A priority patent/AU2002365196C1/en
Publication of WO2003062370A2 publication Critical patent/WO2003062370A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003062370A3 publication Critical patent/WO2003062370A3/fr
Publication of WO2003062370B1 publication Critical patent/WO2003062370B1/fr
Priority to AU2009201466A priority patent/AU2009201466B2/en
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne des polypeptides de multimérisation pouvant assurer la formation de multimères lorsqu'ils sont liés à une molécule, telle qu'une séquence polypeptidique hétérologue.
PCT/US2002/023003 2001-07-19 2002-07-19 Proteines multimeres et methodes de production et d'utilisation de ces proteines Ceased WO2003062370A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003562238A JP2005522192A (ja) 2001-07-19 2002-07-19 マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
EP02804525A EP1578917A4 (fr) 2001-07-19 2002-07-19 Proteines multimeres et methodes de production et d'utilisation de ces proteines
CA002454358A CA2454358A1 (fr) 2001-07-19 2002-07-19 Proteines multimeres et methodes de production et d'utilisation de ces proteines
AU2002365196A AU2002365196C1 (en) 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same
AU2009201466A AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30674601P 2001-07-19 2001-07-19
US60/306,746 2001-07-19
US33542501P 2001-11-30 2001-11-30
US60/335,425 2001-11-30

Publications (3)

Publication Number Publication Date
WO2003062370A2 WO2003062370A2 (fr) 2003-07-31
WO2003062370A3 WO2003062370A3 (fr) 2005-12-15
WO2003062370B1 true WO2003062370B1 (fr) 2006-03-02

Family

ID=27616555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/023003 Ceased WO2003062370A2 (fr) 2001-07-19 2002-07-19 Proteines multimeres et methodes de production et d'utilisation de ces proteines

Country Status (6)

Country Link
US (3) US20030138440A1 (fr)
EP (1) EP1578917A4 (fr)
JP (3) JP2005522192A (fr)
AU (2) AU2002365196C1 (fr)
CA (2) CA2454358A1 (fr)
WO (1) WO2003062370A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039931B1 (fr) * 1997-12-01 2005-04-27 Fang Fang Anticorps de recombinaison multivalents destines au traitement d'infections dues au rhinovirus humain (hrv)
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CA2454358A1 (fr) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Proteines multimeres et methodes de production et d'utilisation de ces proteines
US8475789B2 (en) * 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
WO2009111304A2 (fr) * 2008-02-29 2009-09-11 President And Fellows Of Harvard College État de fusion intermédiaire de hiv-1 gp41 ciblé par des anticorps neutralisant à grande échelle
ME02288B (me) 2010-02-08 2016-02-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CN103917650B (zh) 2011-08-05 2017-10-24 瑞泽恩制药公司 人源化的通用轻链小鼠
CN104066751A (zh) * 2011-11-22 2014-09-24 马里兰州大学(巴尔的摩) 对聚糖具有高亲和力和选择性的lambody及其用途
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
WO2015143414A2 (fr) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Animaux non humains qui produisent des protéines de liaison monodomaine
EP3204041A1 (fr) * 2014-10-10 2017-08-16 Ablynx N.V. Méthodes de traitement d'infections à rsv
EP3271403A1 (fr) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
EP3935079A4 (fr) 2019-03-06 2023-03-22 Cue Biopharma, Inc. Polypeptides de présentation d'antigènes modulateurs de lymphocytes t et leurs procédés d'utilisation
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN114728072A (zh) 2019-10-23 2022-07-08 库尔生物制药有限公司 TGF-β多肽

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562421B1 (fr) 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
EP0169146A3 (fr) 1984-07-20 1988-07-20 Merck & Co. Inc. Anticoprs monoclonaux dirigés contre le récepteur cellulaire du rhinovirus humain
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5077195A (en) * 1985-03-01 1991-12-31 Board Of Reagents, The University Of Texas System Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ES2039203T3 (es) 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5565550A (en) 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
ATE128727T1 (de) 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002569A1 (fr) 1988-09-06 1990-03-22 International Genetic Engineering, Inc. Production d'anticorps chimeriques murins-humains a specificite pour des antigenes de tumeurs humains
ATE125708T1 (de) 1988-09-28 1995-08-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DK0387701T3 (da) 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
US5081584A (en) * 1989-03-13 1992-01-14 United States Of America Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide
AU627591B2 (en) 1989-06-19 1992-08-27 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
WO1991007418A1 (fr) 1989-11-13 1991-05-30 Xoma Corporation Anticorps a10 chimerique souris-humain avec specificite envers un antigene de cellule tumorale humaine
WO1991007493A1 (fr) 1989-11-13 1991-05-30 Xoma Corporation Anticorps murins humains chimeriques a specificite aux antigenes du vih
AU6663990A (en) 1989-11-13 1991-05-16 Green Cross Corporation, The Chimeric mouse-human antibodies with specificity to hiv antigens
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0459577A3 (en) 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0571613B1 (fr) * 1991-12-13 2003-09-17 Xoma Corporation Materiels et methodes pour preparer des domaines variables d'anticorps modifies et leurs utilisations therapeutiques
KR100254759B1 (ko) 1992-01-23 2000-05-01 플레믹 크리스티안 단량체 및 이량체 항체-단편 융합 단백질
US5330101A (en) 1992-02-06 1994-07-19 Nordson Corporation Material changeover and anti-skin over system
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
WO1993019660A1 (fr) 1992-04-03 1993-10-14 Baylor College Of Medicine Therapie genique utilisant l'intestin
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
JPH09510601A (ja) 1993-11-12 1997-10-28 ケース・ウエスタン・リザーブ・ユニバーシティ ヒト遺伝子治療用のエピソーム発現ベクター
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
CA2117668C (fr) 1994-03-09 2005-08-09 Izumu Saito Adenovirus recombinant et son mode de production
JP3348204B2 (ja) 1994-04-20 2002-11-20 三菱アルミニウム株式会社 ろう粉末付長尺物の製造方法および装置
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5721340A (en) 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
JPH11510389A (ja) 1995-07-31 1999-09-14 アメリカ合衆国 細胞タンパク質の機能を不活性化するためのタンパク質−タンパク質相互作用表面の拡張
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997023631A2 (fr) * 1995-12-22 1997-07-03 Somatogen, Inc. Globines incluant des domaines de liaison
CA2239303A1 (fr) * 1995-12-22 1997-07-03 Somatogen, Inc. Globines incluant des domaines de liaison
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
EP1039931B1 (fr) 1997-12-01 2005-04-27 Fang Fang Anticorps de recombinaison multivalents destines au traitement d'infections dues au rhinovirus humain (hrv)
DE19815331A1 (de) * 1998-04-06 1999-10-14 Karlsruhe Forschzent Transkriptionsfaktoren und deren Verwendung
US20020165153A1 (en) 1998-04-06 2002-11-07 Peter Angel Transcription factors and their use
US5965712A (en) 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ATE477273T1 (de) * 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
WO2001019842A1 (fr) 1999-09-17 2001-03-22 Genzyme Transgenics Corporation Proteine de fusion optimisee par des sous-unites
CN101643512A (zh) 2000-04-28 2010-02-10 行星生物技术有限公司 预防鼻病毒感染的新型免疫粘附素
CA2454358A1 (fr) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Proteines multimeres et methodes de production et d'utilisation de ces proteines
JP4236000B2 (ja) 2003-09-25 2009-03-11 元気株式会社 ３次元画像処理装置、３次元画像処理方法及びプログラム

Similar Documents

Publication Publication Date Title
WO2003062370B1 (fr) Proteines multimeres et methodes de production et d'utilisation de ces proteines
US11072640B2 (en) Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
Morinaga et al. Primary structures of human alpha-fetoprotein and its mRNA.
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
AU2012228990A1 (en) Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2023186120A1 (fr) Nanocorps anti-albumine sérique et dérivé de celui-ci
WO2018032637A1 (fr) Protéine de fusion du facteur viii de coagulation sanguine humaine hautement glycosylée, son procédé de fabrication et son application
JP2019506140A5 (fr)
JP2018503355A5 (fr)
AU2002365196B8 (en) Multimeric proteins and methods of making and using same
KR20140135766A (ko) 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법
JP2005522192A5 (fr)
WO2021247675A1 (fr) Agents liant les coronavirus et leurs utilisations
AU2002365196A1 (en) Multimeric proteins and methods of making and using same
WO2014010813A1 (fr) Colonne d'adsorption pour la purification d'anticorps à l'aide d'un peptide de liaison à fc d'un anticorps
JP2008507253A5 (fr)
EP0724593A1 (fr) Matrices en boucle a axe superenroule
JP2009526535A (ja) 新規ｃｃケモカインアンタゴニスト
JP2009513124A (ja) 新規ｃｘｃケモカインアンタゴニスト
JPWO2023285686A5 (fr)
JPS6034994A (ja) 新規ポリペプチドおよびその用途
AU2016204968A1 (en) FGF21 mutants and uses thereof
HK1155669B (en) Fgf21 mutants and uses thereof
HK1155669A (en) Fgf21 mutants and uses thereof